Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 30, 2016

MicuRx begins Phase I trial of MRX-4 against Gram-positive bacteria

US-based biopharmaceutical company MicuRx has begun its Phase I clinical trial of MRX-4, for the treatment of infections caused by Gram-positive bacteria, including methicillin-resistant S. aureus (MRSA) and vancomycin-resistant Enterococci (VRE).

US-based biopharmaceutical company MicuRx has begun its Phase I clinical trial of MRX-4, for the treatment of infections caused by Gram-positive bacteria, including methicillin-resistant S. aureus (MRSA) and vancomycin-resistant Enterococci (VRE).

MRX-4 is a prodrug version of the oral antibiotic MRX-1, an oxazolidinone agent. MRX-4 is suited for both intravenous and enhanced oral applications.

The drug is currently being evaluated within Phase III clinical trials in China for the treatment of complicated skin infections.

The Phase I trial is being conducted to assess the safety and tolerability, as well as determine the pharmacokinetics profile and bioavailability of the oral formulation of MRX-4.

"An oral anti-MRSA agent like MRX-4 with a safety profile appropriate for outpatients and for extended treatment remains an unmet medical need despite recent antibiotic launches."

MicuRx has started enrolling patients at a single centre in the US and is planning to enrol 122 healthy subjects in nine single and four multiple-ascending dose cohorts.

The company will concurrently evaluate the safety, tolerability, and pharmacokinetics of the intravenous formulation of MRX-4 while examining 60 healthy subjects of five single-ascending and four multiple-ascending dose cohorts, along with an oral to IV crossover study. 

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

MicuRx chief medical officer Barry Hafkin said: "An oral anti-MRSA agent like MRX-4 with a safety profile appropriate for outpatients and for extended treatment remains an unmet medical need despite recent antibiotic launches.

"In addition, an IV formulation of the same molecule is highly desirable to allow physicians to treat serious MRSA or VRE infections in hospital, before transitioning to an oral outpatient treatment."

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU